The reverse cholesterol transport system as a potential mediator of luteolysis in the primate corpus luteum

Randy L Bogan² and Jon D Hennebold^{1,2}

¹Division of Reproductive Sciences, Oregon National Primate Research Center, Oregon Health and Science University, West Campus, 505 Northwest 185th Avenue, Beaverton, Oregon 97006, USA and

²Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon 97239, USA

Correspondence should be addressed to J D Hennebold at Division of Reproductive Sciences, Oregon National Primate Research Center, Oregon Health and Science University; Email: henneboj@ohsu.edu

Abstract

The cessation of progesterone (P_4) production (i.e. functional regression), arguably the key event in luteolysis of the primate corpus luteum (CL), is poorly understood. Previously, we found that genes encoding proteins involved in cholesterol uptake decreased, while those involved in cholesterol efflux (reverse cholesterol transport, RCT) increased in expression during spontaneous functional regression of the rhesus macaque CL, thereby potentially depleting the cholesterol reserves needed for steroidogenesis. Therefore, a comprehensive analysis of the components necessary for RCT was performed. RCT components were expressed (mRNA and/or protein) in the macaque CL including cholesterol sensors (liver X receptors α or NR1H3; and β or NR1H2), efflux proteins (ATP-binding cassette subfamilies A1 (ABCA1) and G1), acceptors (apolipoproteins A1 or APOA1; and E or APOE), and plasma proteins facilitating high-density lipoprotein formation (lecithin:cholesterol acyltransferase or LCAT; phospholipid transfer protein or PLTP). ABCA1, APOE, PLTP, and NR1H3 increased, while lipoprotein receptors decreased, in expression (mRNA and/or protein) through the period of functional regression. The expression of APOA1 and APOE, as well as NR1H3, was greatest in the CL and tissues involved in regulating cholesterol homeostasis. Immunolocalization studies revealed that RCT proteins and lipoprotein receptors were expressed in large luteal cells, which possess intracellular cholesterol reserves during periods of P_4 synthesis. Lipid staining revealed changes in luteal cholesterol ester/lipid distribution that occurred following functional regression. These results indicate that decreased cholesterol uptake and increased RCT may be critical for the initiation of primate luteolysis by limiting intracellular cholesterol pools required for steroidogenesis.

Reproduction (2010) **139** 163–176

Introduction

The corpus luteum (CL) produces progesterone (P_4) during the luteal phase of the menstrual cycle, and P_4 is absolutely required to maintain early pregnancy in primates. However, in nonconception cycles, P_4 secretion from the CL must cease to allow for the initiation of the next ovarian cycle. Therefore, understanding the factors controlling CL regression (luteolysis) is of considerable importance. Luteolysis occurs in two phases: 1) a decrease in P_4 synthesis (functional regression), and 2) degradation and structural remodeling of the CL (structural regression; Hoyer 1998, Stouffer 2003). Functional regression must occur before structural regression can proceed due to the luteoprotective effects of P_4 (Hoyer 1998, Stouffer 2003). However, the molecular processes responsible for initiation of functional regression and subsequent structural regression in the primate CL are poorly defined.

Functional regression in primates is characterized by reduced sensitivity to LH as the CL ages (Cameron & Stouffer 1982, Eyster *et al.* 1985, Brannian & Stouffer 1991), and pulses of LH must increase or a more potent LH-receptor ligand (chorionic gonadotropin) must be present to maintain the primate CL by the end of the normal luteal phase (Duffy *et al.* 1999). The mechanisms responsible for the loss of P_4 synthesis in an LH-replete environment are not known. To address this void in our understanding of primate luteolysis, we previously used a microarray approach to identify global changes in gene expression occurring throughout the normal period of functional regression in the primate CL (Bogan *et al.* 2009). From the resultant database, it was noted that genes whose products are involved in cholesterol uptake (low-density lipoprotein receptor or *LDLR*; scavenger receptor type B class 1 or *SCARB1*) decreased in expression, while ATP-binding cassette subfamilies A1 and G1 (*ABCA1* and *ABCG1*) increased during the approximate time when

functional regression occurred. ABCA1 and ABCG1 are two key cholesterol efflux proteins critical for reverse cholesterol transport (RCT), a process whereby excess cholesterol is removed from cells and transported to the liver for elimination as bile or bile acids (Mahley *et al.* 2006). Because steroid hormones are derived from cholesterol, induction of RCT coupled with inhibiting extracellular cholesterol uptake could conceivably cause functional regression in the CL by limiting the substrate necessary for steroidogenesis.

In addition to ABCA1 and ABCG1, the RCT system requires coordination of many proteins including cholesterol sensors (NR1H3/LXR α and NR1H2/LXR β), cholesterol acceptors (apolipoproteins A1 (APOA1) and E (APOE)), and plasma proteins facilitating high-density lipoprotein (HDL) formation (lecithin:cholesterol acyltransferase (LCAT), phospholipid transfer protein (PLTP), and cholesteryl ester transfer protein (CETP)). Unesterified cholesterol and phospholipids are transferred to APOA1, the major protein component of HDL, by the ABC transporters (Mahley *et al.* 2006). The free cholesterol bound to APOA1 is esterified by LCAT thus changing the morphology of the HDL molecule from discoidal to spherical as cholesterol esters are packaged into its hydrophobic core (Jonas 2000). The actions of LCAT allow more cholesterol to be transferred to the HDL molecule (Jonas 2000). In addition to APOA1, APOE also may be an important cholesterol acceptor in RCT as some subclasses of HDL contain APOE (Mahley *et al.* 2006). APOE allows for expansion of the cholesterol ester-rich core, thus increasing the cholesterol-carrying capacity of HDL molecules (Mahley *et al.* 2006). Additionally, APOE is an LDLR ligand and consequently allows HDL clearance via hepatic LDLR and LDLR-related proteins (Mahley 1988, Zaiou *et al.* 2000). Other plasma proteins involved in RCT include PLTP, which promotes the formation of pre- β HDL and thus increases the cholesterol-accepting capacity of plasma (Von Eckardstein *et al.* 1996, Dullaart & Van Tol 2001), and CETP, which transfers cholesterol esters from HDL to APOB-containing lipoproteins (low- or very low-density lipoproteins; Mahley *et al.* 2006).

NR1H2 and NR1H3 are known to stimulate transcription of several important RCT genes including *ABCA1*, *ABCG1*, *PLTP*, *CETP* (Lund *et al.* 2003) and *APOE* (Laffitte *et al.* 2001a), as well as autoregulation of *NR1H3* (Laffitte *et al.* 2001b). They were originally identified as orphan nuclear receptors belonging to the steroid hormone receptor superfamily. They are now known to bind various oxysterols thereby serving as 'cholesterol sensors' that will stimulate RCT in cases of cholesterol excess (Wojcicka *et al.* 2007).

To our knowledge, the presence and functionality of the RCT system in the CL have not been addressed in any species. Based on our previous genomic analysis of macaque luteal tissue obtained through the period of functional regression (Gene Expression Omnibus

accession number GSE12807; Bogan *et al.* 2009), the RCT system may be induced within the primate CL to facilitate the loss in P_4 -producing capacity at the end of nonconception cycles. To this end, the objectives of the current study are to: 1) extend our previous findings of differential mRNA expression of ABCA1 and ABCG1, as well as the lipoprotein receptors LDLR and SCARB1 (Bogan *et al.* 2009), by determining whether their corresponding protein levels are also differentially expressed throughout the normal period of functional regression; 2) determine whether additional components involved in RCT (mRNA or protein) are also expressed in the primate CL (e.g. APOA1, APOE, LCAT, PLTP, CETP, NR1H2, and NR1H3); 3) determine the cellular localization of RCT proteins as well as LDLR and SCARB1, protein expression; and 4) assess changes in cholesterol/lipid handling or storage in the primate CL during its functional regression.

Results

Levels of lipoprotein receptor and ABC transporter proteins in the macaque CL

Levels of SCARB1 were not different between mid-late and functional late CL. However, there was a more than threefold decrease from functional to functionally regressed late stage CL ($P < 0.05$), with SCARB1 being undetectable in very late stage CL (Fig. 1B). There was an approximately twofold decrease in LDLR from mid-late to functional late CL ($P < 0.05$), followed by a > 4 -fold decrease from functional to functionally regressed late CL. LDLR was not detected in very late stage CL (Fig. 1B).

Levels of ABCA1 protein were not different between mid-late and functional late CL, but increased by more than twofold from functional to functionally regressed late stage CL ($P < 0.05$), and continued to rise in the very late stage (Fig. 1C). There were no differences between any groups in levels of ABCG1 protein (Fig. 1C).

Localization of luteal SCARB1, LDLR, ABCA1, and ABCG1

Large luteal cells stained for SCARB1 while there was minimal or no expression in small cell types such as stroma and endothelial cells (Fig. 2). Pre-absorption of the primary antibody with its immunizing peptide resulted in minimal staining. SCARB1 was evident at the plasma membrane during all stages analyzed. LDLR displayed a similar staining pattern as SCARB1 with the majority of expression occurring in large luteal cells (Fig. 2). Staining for LDLR was evident at the plasma membrane of all stages analyzed, and was absent following pre-absorption of the primary antibody with its immunizing peptide.

ABCA1 expression was observed in large luteal cells, as well as in the endothelial cells and adjacent stroma

Figure 1 Lipoprotein receptor and ABC transporter protein levels throughout the period of spontaneous functional regression in the rhesus macaque CL. Panel A contains representative western blots for SCARB1, LDLR, ABCA1, ABCG1, and TUBB using samples pooled from CL collected at either the mid-late (ML), functional late (FL), functionally regressed late (FRL), or very late (VL) stages of the luteal phase. The results of densitometry analyses of individual luteal homogenates ($n=4$ CL/group) for the lipoprotein receptors SCARB1 and LDLR, as well as the cholesterol efflux proteins ABCA1 and ABCG1, are presented in panels B and C, respectively. Error bars indicate one S.E.M. Columns with different letters of the same case are significantly different ($P<0.05$).

lining blood vessels (Fig. 2). ABCA1 expression was diffuse throughout the cell in mid-late and functional late CL, while localization near the plasma membrane in some cells was more evident in functionally regressed late CL. ABCG1 expression was also found in large luteal cells, while staining in small luteal cells or near the vasculature was minimal (Fig. 2). During the mid-late and functional late stages, ABCG1 expression was predominantly perinuclear with some evidence of plasma membrane staining. In functionally regressed late CL, however, increased plasma membrane localization was observed.

CL expression of APOA1 and APOE

Both APOA1 and APOE mRNA were expressed in the macaque CL at all stages of the luteal phase as determined by GeneChip Operating System (GCOS) absolute expression analysis of microarray data (Bogan *et al.* 2008a). APOE mRNA levels were lowest in early CL followed by an increase at each subsequent stage with the exception of a slight decrease between functional and functionally regressed late CL. Quantitative-PCR (Q-PCR) analysis of APOE expression yielded highly similar results, with the early CL being significantly lower than all other groups ($P<0.05$) and the functional late and very late CL being significantly higher ($P<0.05$) than mid or mid-late CL (Fig. 3A). APOA1 had a pattern of expression opposite to APOE as its mRNA levels were highest in the early luteal phase and slowly decreased thereafter with functionally regressed late and very late CL being significantly lower than all other stages as determined by both microarray and Q-PCR (Fig. 3C).

APOE protein was also detected in the CL at all stages of the luteal phase by immunohistochemistry (IHC; Fig. 3B). APOE localized to the large luteal cells, with some interspersed staining also noted in stroma and along vessel endothelial cells. APOE staining was primarily observed in the cytoplasm and perinuclear regions of mid and mid-late CL, with a more diffuse pattern observed in functional and functionally regressed late sections. Strong staining for APOA1 was also detected throughout the luteal phase and in all regions of the primate CL (Fig. 3D). Staining near the plasma membrane of large luteal cells was evident through the functionally regressed late stage, while APOA1 was mostly detected in the cytoplasm of these cells during the very late stage.

CL expression of LCAT, PLTP, and CETP

LCAT and PLTP mRNA were expressed in the macaque CL at all stages of the luteal phase as determined by GCOS absolute expression analysis of microarray data (Bogan *et al.* 2008a). However, CETP mRNA was not detected ($P>0.065$) in 20 of 24 CL, marginally detected

Figure 2 Localization of lipoprotein receptors and ABC transporters in the rhesus macaque CL throughout the period of spontaneous functional regression. Representative photomicrographs of SCARB1, LDLR, ABCA1, and ABCG1 from the mid-late (ML), functional late (FL), functionally regressed late (FRL), and very late (VL) luteal stages are shown. The insets in the upper left corner of the ML samples for SCARB1 and LDLR, as well as in the FRL samples for ABCA1 and ABCG1, are sections that were processed with primary antibody pre-absorbed with immunizing peptide. The approximate locations of various cell types are indicated in the FL panel for each protein and include: large luteal cells (L); small luteal or stromal cells (S); and blood vessels (V). The scale bar in the lower right hand corner of each image is 50 μ m. Arrows indicate the appearance of plasma membrane localization of ABCA1 and ABCG1 in FRL stage CL.

($0.051 > P < 0.065$) in 2 CL (one mid and one functional late), and detected ($P < 0.05$) in only 2 CL (one mid-late and one functionally-regressed late). As *CETP* mRNA was not detected in the majority of CL collected from all stages of the luteal phase, it does not appear that *CETP* is expressed by the primate CL.

LCAT was significantly lower in early and very late CL than all other stages ($P < 0.05$; Fig. 4A). *LCAT* expression did not change from mid to functional late stages, while functionally regressed late CL had *LCAT* levels intermediate of functional late and very late stages ($P < 0.05$). *PLTP* expression did not change from the early to mid-late stages, but increased from the functional late to very late stages (Fig. 4A). The very late CL had significantly higher levels ($P < 0.05$) of *PLTP* than all other stages, and functionally regressed late CL were significantly higher ($P < 0.05$) than early to mid-late stages.

LCAT protein was detected within the CL throughout the luteal phase by IHC (Fig. 4B). Cytoplasmic staining for *LCAT* was noted in large luteal cells, while staining was variable in the stroma. Additionally, *LCAT* staining was evident in the endothelial cells lining the vasculature. *PLTP* protein was also present within the CL (Fig. 4B) and displayed a similar staining pattern as *LCAT* with expression found primarily in large luteal cells, as well as variable staining in the stroma, and more consistent staining in the regions lining blood vessels.

CL expression of *NR1H2* and *NR1H3*

Both *NR1H2* and *NR1H3* were expressed in the CL at all stages of the luteal phase as determined by GCOS absolute expression analysis (Bogan *et al.* 2008a).

Figure 3 Apolipoprotein expression in the rhesus macaque CL. Panel A contains microarray and Q-PCR expression data for *APOE* during the early (E), mid (M), mid-late (ML), functional late (FL), functionally regressed late (FRL), and very late (VL) stages. Error bars indicate one S.E.M. ($n=4$ CL/group). Upper case letters denote significant differences ($P<0.05$) for microarray data and lower case letters denote significant differences for Q-PCR data. Panel B contains representative photomicrographs for *APOE* IHC performed using CL obtained from the E to VL stages of the luteal phase. The inset in the upper left corner of the VL sample is from a control section that was probed with primary antibody pre-absorbed with its immunizing peptide. The approximate locations of various cell types are indicated in the ML panel and include: large luteal cells (L); small luteal or stromal cells (S); and blood vessels (V). The scale bar in the lower right hand corner of each image is 100 μ m. Panel C contains microarray and Q-PCR expression data for *APOA1* that was analyzed in the same manner as for panel A. Panel D contains representative photomicrographs from *APOA1* IHC analysis. The details are similar to the description for panel B except the negative control inset, which is in the FL sample and consists of a control section probed with primary antibody pre-absorbed with purified full-length human *APOA1*.

Levels of *NR1H3* (*LXR α*) did not change from the early to mid-late stages, but significantly increased ($P<0.05$) by the functional late stage and continued to increase through the very late stage as determined by both microarray and Q-PCR (Fig. 5A). Levels of *NR1H2* (*LXR β*) were not different between any groups as determined by microarray. However, Q-PCR analysis of *NR1H2* expression indicated that, while *NR1H2* mRNA did not change from the early to mid-late stages, its levels increased from the mid-late to functionally regressed late stages, with functionally regressed late and very late CL having significantly higher ($P<0.05$) *NR1H2* levels than early to mid-late stages (Fig. 5A). These changes in *NR1H2* levels detected by Q-PCR were not due to cross-amplification of *NR1H3* cDNA as the primers and probe used were designed within a region unique to rhesus *NR1H2*.

Western blot analysis was used to quantify levels of *NR1H2* and *NR1H3* protein during the mid-late to very late stages (Fig. 5B). There were no significant differences between stages in levels of *NR1H2*. Levels of *NR1H3* protein increased by more than threefold from the mid-late to functional late luteal phase ($P<0.05$), with a further increase of more than twofold being detected in very late relative to functionally regressed late CL ($P<0.05$).

Localization of *NR1H2* and *NR1H3*

NR1H2 protein was detected in the large luteal cells as well as in regions adjacent to the endothelial cells lining blood vessels (Fig. 6). During the mid and mid-late stages, *NR1H2* was localized primarily to the cytoplasm of large luteal cells. By the functional late stage, nuclear

localization of NR1H2 became evident in large luteal cells and remained present through the functionally regressed late stage. While NR1H2 protein was still detected in regions of the stroma adjacent to blood vessels during the very late stage, nuclear localization in the large luteal cells was less evident.

NR1H3 protein was detected in the same cell types as NR1H2 including the large luteal cells and regions adjacent to blood vessels (Fig. 6). Staining for NR1H3 in the CL was weak during the mid-late stage, while nuclear localization of NR1H3 was observed in large luteal cells beginning at the functional late stage. Contrary to NR1H2, strong nuclear staining of NR1H3 was still apparent in large luteal cells during the very late stage.

Tissue distribution of APOA1, APOE, NR1H2, and NR1H3 mRNA

APOA1 mRNA levels were greatest in liver, small intestine, and CL, while lower levels were detected in the adrenal, testis, and ovary. There was minimal or nonexistent APOA1 mRNA expression in other tissues analyzed (Fig. 7). APOE mRNA was highly expressed in the CL with comparatively lower levels present in the other steroidogenic/reproductive tissues analyzed (adrenal, uterus, placenta, testis, and ovary). APOE mRNA was also observed in liver, spleen, kidney, small intestine, colon, hypothalamus, and adipose. NR1H2 was detected in all tissues analyzed except brain; however, the housekeeping control for brain was also weakly amplified. High cycle numbers (>30) were needed to detect NR1H2 in most tissues. NR1H3 was expressed in all steroidogenic tissues analyzed, and was especially high in testis and late to very late stage CL. NR1H3 was also highly expressed in liver, spleen, small intestine, and adipose, while heart, lung, lymph node, kidney, stomach, colon, and skeletal muscle displayed lower mRNA levels.

Cholesterol levels and localization

Cholesterol levels in luteal homogenates increased throughout the luteal phase with functionally regressed and very late stages having significantly higher concentrations of cholesterol ($P < 0.05$) than early or mid CL (Fig. 8A). During the mid luteal phase, lipid droplets were abundant throughout large luteal cells. However, functionally regressed late CL were associated with the formation of much larger lipid droplets or aggregates possibly residing in extracellular regions (Fig. 8B).

Figure 4 Expression of proteins that promote HDL formation in the rhesus macaque CL. Panel A contains microarray expression data for LCAT and PLTP during the early (E), mid (M), mid-late (ML), functional late (FL), functionally regressed late (FRL), and very late (VL) stages of the luteal phase. Error bars indicate one S.E.M. ($n = 4$ CL/group). Columns with different letters of the same case are significantly different ($P < 0.05$). Panel B contains representative photomicrographs for LCAT and PLTP IHC analyses. Insets are control sections where the primary antibody was excluded. The approximate locations of various cell types are indicated in the FL (LCAT) or FRL (PLTP) panels and include: large luteal cells (L); small luteal or stromal cells (S); and blood vessels (V). The scale bar in the lower right hand corner of each image is 50 µm.

Figure 5 NR1H2 and NR1H3 expression in the rhesus macaque CL. Panel A contains microarray and Q-PCR expression data for *NR1H2* and *NR1H3* during the early (E), mid (M), mid-late (ML), functional late (FL), functionally regressed late (FRL), and very late (VL) stages of the luteal phase. Panel B contains western blot data for NR1H2 and NR1H3. Images are from pooled CL collected at the ML, FL, FRL, or VL stages. The graph presents densitometry results from analysis of individual CL ($n=4$ CL/group). Error bars indicate one S.E.M. Columns with different letters of the same case are significantly different ($P<0.05$).

Discussion

The initial finding that stimulated further research into the RCT system in the CL was based on the divergent patterns of expression between the ABC transporters and lipoprotein receptors during normal functional regression of the primate CL (Bogan *et al.* 2009). In the current study, the corresponding protein levels were found to parallel previous mRNA results for ABCA1, SCARB1, and LDLR, but not ABCG1. However, ABCG1 expression was maintained throughout the periods covering functional and structural regression. When considered together, there is clearly an increase in the ratio of ABC transporters to lipoprotein receptors in the primate CL near the time of functional regression. ABCA1 is a full-size ABC transporter (i.e. containing two ATP-binding cassettes and two transmembrane domain regions linked together; Kaminski *et al.* 2006), which is involved in HDL metabolism by transferring unesterified cholesterol and phospholipids to lipid-free or lipid-poor APOA1 or APOE (Mahley *et al.* 2006). ABCG1 is a half-size ABC transporter, which has been reported to cooperate with ABCA1 in cholesterol export by transferring cholesterol to nascent or pre- β HDL particles, but not lipid-free APOA1 (Gelissen *et al.* 2006). In murine macrophages, ABCA1 and ABCG1 are additive with regard to cholesterol efflux (Wang *et al.* 2007).

Expression of ABCA1, ABCG1, SCARB1, and LDLR was localized primarily to the large luteal cells. These large cells have intracellular cholesterol reserves during the luteal phase, which serve as a substrate for P_4 synthesis (Niswender *et al.* 2000, Stouffer 2006). The high steroidogenic output of the CL, estimated at up to 40 mg of P_4 per day in humans (Lipsett 1978), relies primarily on blood-borne cholesterol as *de novo* synthesis is only important under severely lipid-deprived states (Gwynne & Strauss 1982, Niswender *et al.* 2000, Stouffer 2006). Thus, the balance between cholesterol uptake and efflux is likely the primary factor regulating levels of intracellular cholesterol stores. Staining for SCARB1, LDLR, and ABCG1 within the nonsteroidogenic stroma was rarely observed. However, ABCA1 was also frequently expressed in regions adjacent to blood vessels. As expected for cell surface receptors, staining for SCARB1 and LDLR was observed near the plasma membrane at all stages analyzed, although SCARB1 had more pronounced membrane localization. This is likely due to differences in the lipid uptake mechanism between the two receptors as the LDLR works by receptor-mediated endocytosis, which may result in its distribution between the cytoplasm and plasma membrane, whereas SCARB1 works via a selective uptake pathway not involving internalization of the receptor (Glass *et al.* 1983, Reaven *et al.* 1984). In contrast, ABCA1 and ABCG1 were primarily expressed in the cytoplasmic and perinuclear regions, with plasma

membrane staining observed more frequently in functionally regressed late CL. It has been reported that ABCG1 localization is redistributed from intracellular sites to the plasma membrane following treatment with NR1H2/NR1H3 agonists (Wang *et al.* 2006). Additionally, ABCA1 may be important for intracellular cholesterol movement. ABCA1 expression has been found in

early and late endosomes and lysosomes, the golgi complex, as well as the plasma membrane with trafficking of ABCA1 occurring between these sites (Orso *et al.* 2000, Neufeld *et al.* 2001). Certain ABCA1 mutants found in Tangier's disease (familial HDL-deficiency syndrome) fail to redistribute to the plasma membrane (Tanaka *et al.* 2003), and mice with targeted inactivation of ABCA1 have impaired cellular lipid trafficking via the *trans*-golgi secretory pathway (Orso *et al.* 2000). Thus, ABCA1 and ABCG1 redistribution within the cell may be important for RCT and may represent another mechanism whereby RCT is regulated in addition to changes in their expression.

Because apolipoproteins are produced in the liver or other tissues and secreted into the bloodstream, synthesis of apolipoproteins within the CL is not a prerequisite for RCT to occur. However, the overall level of cholesterol efflux may be limited by the amount of apolipoprotein acceptors (Santamarina-Fojo *et al.* 2001). As the CL is a highly steroidogenic tissue with large cholesterol reserves (Niswender *et al.* 2000, Stouffer 2006), intraluteal synthesis of apolipoprotein acceptors may be necessary to support the large amounts of cholesterol that would need to be disposed of during functional regression. Both *APOA1* and *APOE* mRNA were expressed throughout the luteal phase, and relative microarray expression units of both genes ranged from ~2300 up to 8500, levels several-fold higher than other RCT genes analyzed in the current study. This indicates that the primate CL may synthesize large amounts of lipoproteins that could serve as cholesterol acceptors during RCT. *APOA1* expression has been primarily attributed to the liver and small intestine (Yokoyama 2006), which is consistent with our semi-quantitative PCR (SQ-PCR) data. We also detected strong *APOA1* expression in the CL, as well as appreciable levels in other steroidogenic tissues including testis, ovary, and adrenal gland. *APOE* was more widely expressed than *APOA1*, although the CL had *APOE* levels higher or comparable to tissues richest in *APOE* such as the liver and adipose. While both *APOA1* and *APOE* were expressed at high levels throughout the luteal phase, their patterns of expression were nearly opposite as *APOA1* steadily decreased, while *APOE* increased from the early to very late stages. This indicates that the two genes are under different transcriptional control in the CL, and rising levels of *APOE* may compensate for decreasing *APOA1*.

APOA1 and *APOE* proteins were detected in the CL by IHC. Because these are circulating proteins, their presence in the CL may be a result of both intraluteal and extraluteal sources, although intracellular staining is likely due to intraluteal synthesis. In steroidogenic tissues, the uptake of cholesterol esters from HDL occurs without internalization of the corresponding lipoproteins (Glass *et al.* 1983, Reaven *et al.* 1984) such that nonluteal sources of *APOA1* and *APOE* would likely

Figure 6 Localization of NR1H2 and NR1H3 expression in the rhesus macaque CL throughout the period of spontaneous functional regression. Representative photomicrographs of NR1H2 and NR1H3 from the mid-late (ML), functional late (FL), functionally regressed late (FRL), and very late (VL) stages are shown. The insets in the upper left corner of the FL 200 $\times$ panel for NR1H2, and FRL panel for NR1H3, are control sections incubated with primary antibody pre-absorbed with its immunizing peptide (NR1H2), or where the primary antibody was excluded (NR1H3). The approximate locations of various cell types are indicated in the FL panel for each protein and include: large luteal cells (L); small luteal or stromal cells (S); and blood vessels (V). The scale bar in the lower right hand corner of each image is 50 μ m.

Figure 7 Tissue distribution of *APOA1*, *APOE*, *NR1H2*, and *NR1H3* gene expression in the rhesus macaque. Agarose gel images of PCR amplification products are shown. Gene-specific primers were used to amplify cDNA collected from various rhesus macaque tissues. The number of cycles used in each image is: *APOA1*=25, *APOE*=24, *NR1H2*=34, *NR1H3*=26, and *PPIA*=26. These cycle numbers correspond approximately with the mid-linear range of amplification for each gene as determined from pooled luteal cDNA. A 100 bp ruler is included with each image, and the 500 bp band is marked. Expected product size for each gene is indicated.

remain extracellular. APOE was found in large luteal cells, in scattered regions of the stroma, and in the lining of blood vessels. APOE was predominantly localized intracellularly, especially in the perinuclear region during the mid and mid-late stages. By the late stage (functional or functionally regressed), APOE appeared more diffuse throughout the cytoplasm. Intracellular and total luteal staining for APOE was noticeably reduced by the very late stage as compared with the early to functional late stages, which is in contrast to its mRNA levels. Besides the fact that IHC is not a quantitative procedure, there could be a number of reasons for this apparent discrepancy including: 1) APOE mRNA levels do not match its protein levels; 2) the extraluteal contribution to APOE staining is unknown and may be lower in the functionally regressed late to very late stages due to decreased lipoprotein receptor expression; and 3) intraluteal APOE protein synthesis parallels mRNA levels and differences in staining intensity are due to changes in the rate of APOE secretion from luteal cells. The latter possibility is arguably the most probable explanation as the staining pattern observed is consistent with intraluteal synthesis and storage of APOE during periods of high P_4 production (mid and mid-late), followed by an enhanced secretion of APOE during

functional and structural regression. Strong staining for APOA1 was observed throughout the luteal phase, with a large contribution possibly coming from extraluteal sources. Staining along the plasma membrane was noticed from the early to functionally regressed late stages, possibly due in large part to extraluteal APOA1 bound to SCARB1. However, during the very late stage when SCARB1 is virtually absent, APOA1 localization to the plasma membrane was less pronounced while cytoplasmic APOA1 staining remained strong, consistent with intraluteal synthesis.

Similar to the apolipoproteins, luteal expression of LCAT and PLTP is not absolutely required for RCT to occur as they can arrive via the bloodstream from extraluteal sources. However, intraluteal synthesis of these proteins may enhance the efficiency of the RCT system in the CL. Both *LCAT* and *PLTP* mRNA were expressed in the CL throughout the luteal phase. Furthermore, both proteins were detected in the CL by IHC. Intracellular staining was found in large luteal cells. The nonsteroidogenic stroma was mostly devoid of LCAT and PLTP except for small patches of staining. Also, staining was present in regions immediately adjacent to blood vessels. This pattern of expression is consistent with intraluteal synthesis of LCAT and PLTP by large

luteal cells, followed by their subsequent secretion. LCAT is functionally dependant on APOA1, and to a lesser extent APOE, as LCAT specifically interacts with and is activated by these apolipoproteins (Jonas 2000).

NR1H2 and NR1H3 are key regulators of the RCT system. In mice, *NR1H3* is highly expressed in the liver, intestine, and adipose; but was reported to be present at low or nondetectable levels in steroidogenic tissues such as the adrenal, testis, and ovary (Repa & Mangelsdorf 2000). Based on our SQ-PCR data, it appears that in the macaque *NR1H3* is also highly expressed in the liver, small intestine, and adipose as was reported in mice. High levels of *NR1H3* were also noted in the macaque spleen, testis, and CL. In contrast, *NR1H2* is ubiquitously expressed in mice (Repa & Mangelsdorf 2000), which is consistent with our findings in the macaque whereby *NR1H2* mRNA levels were similar in most tissues. In the macaque CL, there was a significant increase in *NR1H3* mRNA and protein prior to the drop in serum P_4 levels (mid-late to functional late). Both *NR1H2* and *NR1H3* were expressed within the same cell types of the CL. Their expression within large luteal cells overlaps with the localization of other RCT proteins analyzed in the current study. Genes reported to be transcriptional targets of *NR1H2* and *NR1H3* include: *ABCA1*, *ABCG1*, *PLTP*, and *CETP* (Lund *et al.* 2003), *NR1H3* (Laffitte *et al.* 2001b), as well as *APOE* (Laffitte *et al.* 2001a). With the exception of *CETP*, which was not expressed in the macaque CL, our previous (Bogan *et al.* 2009) and current findings are consistent with an activation of *NR1H2* and *NR1H3* in the primate CL near the time of functional regression based on increased *ABCA1*, *ABCG1*, *PLTP*, *NR1H3*, and *APOE* mRNA levels.

This report is the first to detail the presence of components necessary for a functional RCT system in the CL of any species. The only other report on the RCT system that is relevant to the CL came from studies utilizing luteinizing granulosa cells obtained from women undergoing IVF (Drouineaud *et al.* 2007). In that study, synthetic *NR1H2*/*NR1H3* agonists

Figure 8 Rhesus macaque luteal cholesterol levels and cholesterol ester/lipid droplet localization prior to and following spontaneous functional regression. Panel A contains normalized cholesterol concentrations in CL extracts from the early (E), mid (M), mid-late (ML), functional late (FL), functionally regressed late (FRL), and very late (VL) stages of the luteal phase. Error bars indicate one S.E.M. Columns with different letters of the same case are significantly different ($P < 0.05$). Representative lipid droplet staining and localization results, as determined by confocal microscopy, are presented in panel B for the mid and functionally regressed late stages. Actin is represented by blue fluorescence, nuclei are red, and neutral lipids including cholesterol esters are green. The inset in the mid 400 $\times$ lipid overlay is a parallel section that was extracted with methanol to remove all lipids (background control). The approximate locations of various cell types are indicated in the first image for each stage and include: large luteal cells (L); small luteal or stromal cells (S); and blood vessels (V). The scale bar in the lower right hand corner of each image is 50 μ m.

inhibited P_4 synthesis while stimulating mRNA expression of *ABCA1*, *ABCG1*, *APOE*, *PLTP*, and *NR1H3* (Drouineaud *et al.* 2007). In the present study, expression of all components necessary for a functional RCT system was found within the macaque CL, and particularly within large luteal cells, including cholesterol sensors (NR1H2 and NR1H3), cholesterol efflux proteins (ABCA1 and ABCG1), cholesterol acceptors (APOA1 and APOE), as well as plasma proteins critical for HDL maturation (LCAT and PLTP). The mRNA and/or protein levels of known NR1H2/NR1H3 target genes underwent dynamic changes near the time of functional regression in the macaque CL consistent with an induction of these receptors and consequently RCT during this period. It seems logical that an induction of RCT activity in the CL could deplete cholesterol stores and subsequently inhibit P_4 synthesis. Surprisingly, however, cholesterol concentrations in luteal homogenates increased throughout the luteal phase including the period of functional regression. Analysis of lipid droplets within luteal tissue indicated that clear differences in cholesterol ester/lipid storage or localization had occurred between fully functional (mid CL) and functionally regressed late CL. Following functional regression, droplets that were noticeably larger compared to mid CL were present, with some appearing to reside in the extracellular space. Thus, cholesterol appears to be sequestered from the steroidogenic machinery in the form of these large droplets, but is not necessarily completely removed or cleared from the tissue. Collectively, these results indicate that the RCT system may be induced in the primate CL near the time of functional regression, and consequently, may play an integral role in the cessation of P_4 synthesis and ultimately luteolysis. Future studies are needed to further define the functional importance of the RCT system in the primate CL.

Materials and Methods

CL collection

All animal protocols were approved by the Oregon National Primate Research Center's Institutional Animal Care and Use Committee. Regularly cycling female rhesus macaques between 5 and 10 years of age were used for these studies. The care and handling of rhesus macaques was performed as described previously (Wolf *et al.* 1990). CL collected between days 10–12 (mid-late stage), 14–16 (late stage), and 18–19 (very late stage) after the midcycle LH surge were used for analysis as these stages encompass the periods immediately preceding functional regression (mid-late stage), during functional regression (late stage), and structural regression (very late stage, menses). The late stage CL were further divided into two groups ($n=4$ CL/group) based on serum concentrations of P_4 with CL from animals maintaining high serum levels of P_4 (5.4 ± 1.2 ng/ml) considered to be functional late stage CL, and CL from animals having low serum levels of P_4 (0.4 ± 0.1 ng/ml) considered to be functionally-regressed late

stage CL as described previously (Bogan *et al.* 2009). In some cases, CL collected between days 3–5 (early stage, developing CL) and 7–8 (mid stage, fully functional CL) were also included in the analyses.

mRNA quantification by microarray and Taqman Q-PCR analyses

Microarray expression data were obtained using raw fluorescence intensity files (.cel files) from two previously published microarray experiments (Bogan *et al.* 2008a, 2009) that are accessible through the NCBI GEO database (accession numbers GSE10367 and GSE12807; <http://www.ncbi.nlm.nih.gov/geo/>). The raw expression intensities corresponding to early, mid, mid-late, and very late stages (Bogan *et al.* 2008a), as well as functional and functionally regressed late stages (Bogan *et al.* 2009) were normalized by the robust multichip average algorithm (Irizarry *et al.* 2003) using Affymetrix Expression Console version 1.0 software. Probe sets corresponding to *APOA1*, *APOE*, *LCAT*, *PLTP*, *CETP*, *NR1H2*, and *NR1H3* were located (<http://www.affymetrix.com/analysis/index.affx>) and used to isolate their expression data from the newly generated microarray expression database.

To determine whether or not a gene was expressed in the macaque CL, a database containing GCOS absolute expression analysis data was referenced. This database was developed by the Affymetrix Microarray Core of the Oregon Health & Science University Gene Microarray Shared Resource. For each individual GeneChip genome array hybridization performed as part of two previous microarray projects (Bogan *et al.* 2008a, 2009), a GCOS absolute expression analysis was performed on nonnormalized data with parameters α_1 and α_2 set to 0.05 and 0.065 (Affymetrix defaults) respectively. These parameters determine whether a transcript is detected and therefore present (P) ($P \leq 0.05$), marginally detected ($P = 0.051$ – 0.065), or not detected and thus considered not to be expressed within the CL ($P > 0.065$).

Q-PCR was performed as described previously (Bogan *et al.* 2008a) with the exception that target genes were normalized to mitochondrial ribosomal protein S10 (*MRPS10*). Primer and probe sequences used for Q-PCR analysis are provided in Table 1.

SQ-PCR was performed using cDNA generated from various rhesus macaque tissues. RT-PCR was performed using 1 μ g RNA, and the cDNA was diluted to a 100 μ l final volume as described elsewhere (Bogan *et al.* 2008a). Primers were designed using Vector NTI software (Informax, Inc., Bethesda, MD, USA) to amplify a region of 200–700 bps in length and were contained within regions of each gene that are homologous among all known transcript variants. Primer sequences and annealing temperatures used in the PCR reactions are provided in Table 1. PCR reactions utilized 6 μ l cDNA and 400 nM gene-specific primers in a 30 μ l reaction. The reactions were stopped at three different cycle numbers to allow collection of 10 μ l aliquots. After addition of 5 $\times$ nucleic acid-loading buffer (Bio-Rad), 5 μ l PCR product (10 μ l for NR1H2) was resolved by 1% agarose (w/v) gel electrophoresis. To estimate the linear range of amplification, PCR was performed using CL cDNA, and the reactions were terminated

Table 1 Individual gene information for Q-PCR and SQ-PCR analyses.

Gene symbol	Forward primer (5'–3')	Reverse primer (5'–3')	Probe (5'–3'): 6FAM-sequence-MGBNFQ MRPS10 only: VIC-sequence-MGBNFQ
Q-PCR forward and reverse primers as well as MGB probe sequences			
APOA1	ACTCAAAGACAGCGGCAAAGA	GTCCCAGTTGTCCAGGAGCTT	CCTTCAAACCTGGGACACATA
APOE	CTGGGTGCAGACACTGTCTGA	GCTGTTCTCCAGTCCGATT	TCAACTCCTTCATGGTCTCA
NR1H2	GGGAACTGGACTTTCGTCTCAA	GAAACATTGCTGGGTGAATGTC	TCTCTAGAATGGTCAACCCAG
NR1H3	TGTGCACGAATGACTGTTCTTTT	CCCTTCTCAGTCTGTTCCACTTC	ATCCGGCCCCAGAAAACAAAA
MRPS10	AATGTGCCCCAACCTTCATGTC	TCCAGGCAAACCTGTTCTTCA	TGAAGGCCATGCAGTCTCTCAAGTCCC
Gene symbol	Forward primer (5'–3')	Reverse primer (5'–3')	Annealing temperature (°C)
SQ-PCR forward and reverse primer sequences and annealing temperature used in PCR reaction			
APOA1	CCACGGCCCTTCAGGATGAA	TCAGATGCTCGCTGGCCTTG	64
APOE	GTCGCTTTTGGGATTACCTG	TGCTCCTTCACCTCGTCCAG	53
NR1H2	TACAGGACAAGAAGCTACCG	ACATGCTCAATCAGGTTTCA	55
NR1H3	CAGAGAGGAAGCCAGGATGC	CACTTGCGAAGCCGACACTC	62
PPIA	CCAGGGTTTATGTGTCAGGG	TGCCTTCTTCACTTTGCCA	56

at 21, 24, 27, 30, 33, and 36 cycles. Based on these results (data not shown), SQ-PCR was performed on cDNA from 21 different tissues, and three different cycle numbers were attempted for each gene corresponding to mid-linear range, just prior to saturation, and post-saturation. Cyclophilin A (PPIA) was used as a housekeeping control.

Western blot analysis

Rabbit MABs produced against human antigens corresponding to SCARB1 (clone EP1556Y, catalog no. 1971), LDLR (clone EP1553Y, catalog no. 1956), and ABCG1 (clone EP1366Y, catalog no. 1945) were purchased from Epitomics, Inc. (Burlingame, CA, USA). Mouse MABs produced against human antigens were used for ABCA1 (clone AB.H10, catalog no. sc-58219, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and NR1H3 (clone PPZ0412, catalog no. PP-PPZ0412, R&D Systems, Minneapolis, MN, USA). A rabbit polyclonal antibody produced against human NR1H2 was purchased from Aviva Systems Biology (San Diego, CA, USA; catalog no. ARP38906).

Either 12 µg (ABCA1), 20 µg (SCARB1 and NR1H2), 30 µg (ABCG1 and LDLR), or 50 µg (NR1H3) protein were loaded into individual wells. Antibodies were used at the following concentrations: anti-ABCA1, 0.2 µg/ml; anti-ABCG1, 0.017 µg/ml; anti-LDLR, 0.14 µg/ml; anti-SCARB1, 0.027 µg/ml; anti-NR1H2, 1 µg/ml; anti-NR1H3, 1.25 µg/ml. Protein levels from individual CL ($n=4$ CL/stage) were normalized to β -tubulin (TUBB), and western blot procedures and subsequent densitometry analysis were performed as described previously (Bogan *et al.* 2008a, 2008b).

Immunohistochemistry

The anti-ABCG1, LDLR, SCARB1, NR1H2, and NR1H3 antibodies used in western blot analysis were also used for IHC. For ABCA1, a rabbit polyclonal antibody (catalog no. NB400-105) produced against human ABCA1 was purchased from Novus Biologicals, Inc. (Littleton, CO, USA). A rabbit polyclonal antibody against human APOE (catalog no. 1831) and rabbit MAB against human LCAT (clone EPR1384Y, catalog no. 2013) were purchased from Epitomics, Inc. A chicken

polyclonal antibody produced against human APOA1 was purchased from GenWay Biotech, Inc. (San Diego, CA, USA; catalog no. 15-288-20069F), and a mouse MAB produced against human PLTP was from GeneTex, Inc. (Irvine, CA, USA; clone 2F3-G4, catalog no. GTX90539). Antibodies were used at the following concentrations: anti-ABCA1, 3 µg/ml; anti-ABCG1, 0.33 µg/ml; anti-LDLR, 0.875 µg/ml; anti-SCARB1, 0.27 µg/ml; anti-APOE, 0.46 µg/ml; anti-APOA1, 2 µg/ml; anti-LCAT, 0.19 µg/ml; anti-PLTP, 5 µg/ml; anti-NR1H2, 3 µg/ml; anti-NR1H3, 20 µg/ml. Specificity was determined by probing a CL section with primary antibody that had been pre-absorbed with its immunizing peptide if available (anti-ABCA1, ABCG1, LDLR, SCARB1, APOE, APOA1, and NR1H2), or the primary antibody was excluded if no peptide was available for pre-absorption (anti-LCAT, PLTP, and NR1H3). CL sections from two to three animals per stage were analyzed for each antibody. IHC analysis and image capture were performed as described previously (Bogan *et al.* 2008b).

Cholesterol quantification and localization

Cholesterol was extracted according to a published protocol with minor modifications (McDonald *et al.* 2007). Briefly, frozen CL were homogenized in 3 ml PBS followed by the addition of 6.6 ml of a chloroform/methanol (1:1 v:v) solution, and were vortexed for 2 min. Samples were centrifuged at 1400 *g* for 5 min, and the lower organic layer was transferred to a new tube. Samples were dried under an air stream in a 37 °C water bath and resuspended in 2 ml toluene. The lipid extracts were run over a 100 mg silica solid-phase extraction column (Biotage AB, Charlottesville, VA, USA) pre-conditioned with 2 ml hexane and washed with 1 ml hexane. Cholesterol was eluted with 8 ml of 0.5% (v:v) isopropanol in hexane, dried down, and resuspended in 500 µl methanol. Cholesterol concentrations were determined using a fluorometric assay kit (Cayman Chemical Co., Ann Arbor, MI, USA) following the manufacturer's recommendations with slight modifications. A final volume of 1 µl of all unknowns was used for the assay, and the methanol concentration was held constant at 1% in all unknowns and standards. Total cholesterol content was normalized to tissue weight.

For lipid droplet analysis, fresh frozen CL collected at either the mid or functionally regressed late stages were cut in 10 μ m slices. Sections were fixed with 4% paraformaldehyde and 1% calcium chloride (w:v) in TBS for 10 min at room temperature, and washed in three changes of PBS. Sections were blocked for 30 min at room temperature with Image-iT Signal Enhancer (Invitrogen Co). Sections were stained with spectrally distinct fluorophores for actin (phalloidin-Alexa Fluor 350 conjugate, Invitrogen), nuclei (TO-PRO-3 iodide, Invitrogen), and neutral lipids including cholesterol esters (LipidTox, Invitrogen) following the manufacturer's recommendations. A negative control for neutral lipid fluorescence was included consisting of a section extracted with methanol for 15 min at room temperature. Slides were imaged using a Leica TCS SP spectral confocal imaging system.

Statistical analyses

Normalized microarray, Q-PCR, and western blot data were log transformed if necessary to stabilize variance. Data were analyzed using one-way ANOVA followed by pairwise comparisons with the Student-Newman-Keuls test, and differences were considered statistically significant at $P < 0.05$.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the following National Institutes of Health grants: U54 HD55744 (J D Hennebold), R01 HD42000 (J D Hennebold), RR00163 (J D Hennebold), and T32 training grant HD007133 (R L Bogan).

Acknowledgements

The authors would like to thank Dr Ov Slayden who provided the microscope and camera for capturing digital photomicrographs, as well as technical assistance on their use. The authors also would like to thank to Dr Marina Peluffo for assistance with confocal microscopy image capture, and Ms Melinda Murphy for general laboratory technical assistance. We would also like to thank the following core facilities at the Oregon National Primate Research Center: Molecular and Cellular Biology Core (Drs Eliot Spindel and Yibing Ja); and the Imaging and Morphology Core (Dr Anda Cornea and Ms Barbara Mason).

References

Bogan RL, Murphy MJ, Stouffer RL & Hennebold JD 2008a Systematic determination of differential gene expression in the primate corpus luteum during the luteal phase of the menstrual cycle. *Molecular Endocrinology* **22** 1260–1273.

- Bogan RL, Murphy MJ, Stouffer RL & Hennebold JD 2008b Prostaglandin synthesis, metabolism, and signaling potential in the rhesus macaque corpus luteum throughout the luteal phase of the menstrual cycle. *Endocrinology* **149** 5861–5871.
- Bogan RL, Murphy MJ & Hennebold JD 2009 Dynamic changes in gene expression that occur during the period of spontaneous functional regression in the rhesus macaque corpus luteum. *Endocrinology* **150** 1521–1529.
- Brannian JD & Stouffer RL 1991 Progesterone production by monkey luteal cell subpopulations at different stages of the menstrual cycle: changes in agonist responsiveness. *Biology of Reproduction* **44** 141–149.
- Cameron JL & Stouffer RL 1982 Gonadotropin receptors of the primate corpus luteum. II. Changes in available luteinizing hormone- and chorionic gonadotropin-binding sites in macaque luteal membranes during the nonfertile menstrual cycle. *Endocrinology* **110** 2068–2073.
- Drouineaud V, Sagot P, Garrido C, Logette E, Deckert V, Gambert P, Jimenez C, Staels B, Lagrost L & Masson D 2007 Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists. *Molecular Human Reproduction* **13** 373–379.
- Duffy DM, Stewart DR & Stouffer RL 1999 Titrating luteinizing hormone replacement to sustain the structure and function of the corpus luteum after gonadotropin-releasing hormone antagonist treatment in rhesus monkeys. *Journal of Clinical Endocrinology and Metabolism* **84** 342–349.
- Dullaart RP & Van Tol A 2001 Role of phospholipid transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. *Scandinavian Journal of Clinical and Laboratory Investigation* **61** 69–74.
- Eyster KM, Ottobre JS & Stouffer RL 1985 Adenylate cyclase in the corpus luteum of the rhesus monkey. III. Changes in basal and gonadotropin-sensitive activities during the luteal phase of the menstrual cycle. *Endocrinology* **117** 1571–1577.
- Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, Cartland S, Packianathan M, Kritharides L & Jessup W 2006 ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. *Arteriosclerosis, Thrombosis, and Vascular Biology* **26** 534–540.
- Glass C, Pittman RC, Weinstein DB & Steinberg D 1983 Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. *PNAS* **80** 5435–5439.
- Gwynne JT & Strauss JF III 1982 The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands. *Endocrine Reviews* **3** 299–329.
- Hoyer PB 1998 Regulation of luteal regression: the ewe as a model. *Journal of the Society for Gynecologic Investigation* **5** 49–57.
- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U & Speed TP 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* **4** 249–264.
- Jonas A 2000 Lecithin cholesterol acyltransferase. *Biochimica et Biophysica Acta* **1529** 245–256.
- Kaminski WE, Piehler A & Wenzel JJ 2006 ABC A-subfamily transporters: structure, function and disease. *Biochimica et Biophysica Acta* **1762** 510–524.
- Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ & Tontonoz P 2001a LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. *PNAS* **98** 507–512.
- Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL & Tontonoz P 2001b Autoregulation of the human liver X receptor alpha promoter. *Molecular and Cellular Biology* **21** 7558–7568.
- Lipsett MB 1978 Steroid hormones. In *Reproductive Endocrinology*, pp 80–92. Eds SC Yen & RB Jaffe. Philadelphia: WB Saunders Press.
- Lund EG, Menke JG & Sparrow CP 2003 Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology* **23** 1169–1177.
- Mahley RW 1988 Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* **240** 622–630.
- Mahley RW, Huang Y & Weisgraber KH 2006 Putting cholesterol in its place: apoE and reverse cholesterol transport. *Journal of Clinical Investigation* **116** 1226–1229.

- McDonald JG, Thompson BM, McCrum EC & Russell DW 2007 Extraction and analysis of sterols in biological matrices by high performance liquid chromatography electrospray ionization mass spectrometry. *Methods in Enzymology* **432** 145–170.
- Neufeld EB, Remaley AT, Demosky SJ, Stonik JA, Cooney AM, Comly M, Dwyer NK, Zhang M, Blanchette-Mackie J, Santamarina-Fojo S *et al.* 2001 Cellular localization and trafficking of the human ABCA1 transporter. *Journal of Biological Chemistry* **276** 27584–27590.
- Niswender GD, Juengel JL, Silva PJ, Rollyson MK & McIntush EW 2000 Mechanisms controlling the function and life span of the corpus luteum. *Physiological Reviews* **80** 1–29.
- Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, Gotz A, Chambenoit O, Diederich W, Langmann T *et al.* 2000 Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. *Nature Genetics* **24** 192–196.
- Reaven E, Chen YD, Spicher M & Azhar S 1984 Morphological evidence that high density lipoproteins are not internalized by steroid-producing cells during *in situ* organ perfusion. *Journal of Clinical Investigation* **74** 1384–1397.
- Repa JJ & Mangelsdorf DJ 2000 The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. *Annual Review of Cell and Developmental Biology* **16** 459–481.
- Santamarina-Fojo S, Remaley AT, Neufeld EB & Brewer HB Jr 2001 Regulation and intracellular trafficking of the ABCA1 transporter. *Journal of Lipid Research* **42** 1339–1345.
- Stouffer RL 2003 Progesterone as a mediator of gonadotrophin action in the corpus luteum: beyond steroidogenesis. *Human Reproduction Update* **9** 99–117.
- Stouffer RL 2006 Structure, function, and regulation of the corpus luteum. In *The Physiology of Reproduction*, edn 3, pp 475–526. Eds E Knobil & JD Neill. New York: Raven Press.
- Tanaka AR, Abe-Dohmae S, Ohnishi T, Aoki R, Morinaga G, Okuhira K, Ikeda Y, Kano F, Matsuo M, Kioka N *et al.* 2003 Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis. *Journal of Biological Chemistry* **278** 8815–8819.
- Von Eckardstein A, Jauhiainen M, Huang Y, Metso J, Langer C, Pussinen P, Wu S, Ehnholm C & Assmann G 1996 Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL. *Biochimica et Biophysica Acta* **1301** 255–262.
- Wang N, Ranalletta M, Matsuura F, Peng F & Tall AR 2006 LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. *Arteriosclerosis, Thrombosis, and Vascular Biology* **26** 1310–1316.
- Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR & Rader DJ 2007 Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport *in vivo*. *Journal of Clinical Investigation* **117** 2216–2224.
- Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K & Beltowski J 2007 Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. *Postepy Higieny I Medycyny Doswiadczalnej* **61** 736–759.
- Wolf DP, Thomson JA, Zelinski-Wooten MB & Stouffer RL 1990 *In vitro* fertilization-embryo transfer in nonhuman primates: the technique and its applications. *Molecular Reproduction and Development* **27** 261–280.
- Yokoyama S 2006 Assembly of high-density lipoprotein. *Arteriosclerosis, Thrombosis, and Vascular Biology* **26** 20–27.
- Zaiou M, Arnold KS, Newhouse YM, Innerarity TL, Weisgraber KH, Segall ML, Phillips MC & Lund-Katz S 2000 Apolipoprotein E – low density lipoprotein receptor interaction. Influences of basic residue and amphipathic alpha-helix organization in the ligand. *Journal of Lipid Research* **41** 1087–1095.

Received 6 January 2009

First decision 18 February 2009

Revised manuscript received 24 August 2009

Accepted 22 September 2009